Literature DB >> 8866184

Clinical mycobacteriology. Drug susceptibility testing.

L B Heifets1.   

Abstract

An update on drug susceptibility testing is provided on methods for testing Mycobacteria tuberculosis, Mycobacteria avium, and rapidly growing mycobacteria. Emphasis is placed on the techniques that are currently available in clinical laboratories, and a critical overview is offered for some methods undergoing development.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8866184

Source DB:  PubMed          Journal:  Clin Lab Med        ISSN： 0272-2712            Impact factor:   1.935


  9 in total

1.  Development of rifapentine susceptibility tests for Mycobacterium tuberculosis.

Authors:  L Heifets; T Sanchez; J Vanderkolk; V Pham
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

2.  Assessing spatiotemporal patterns of multidrug-resistant and drug-sensitive tuberculosis in a South American setting.

Authors:  H Lin; S Shin; J A Blaya; Z Zhang; P Cegielski; C Contreras; L Asencios; C Bonilla; J Bayona; C J Paciorek; T Cohen
Journal:  Epidemiol Infect       Date:  2010-12-23       Impact factor: 2.451

3.  Impact of rapid drug susceptibility testing for tuberculosis: program experience in Lima, Peru.

Authors:  S S Shin; L Asencios; M Yagui; G Yale; C Suárez; J Bayona; C Bonilla; O Jave; C C Contreras; S Atwood; J A Blaya; J Ershova; J P Cegielski
Journal:  Int J Tuberc Lung Dis       Date:  2012-09-14       Impact factor: 2.373

4.  A novel inhibitor of gyrase B is a potent drug candidate for treatment of tuberculosis and nontuberculosis mycobacterial infections.

Authors:  Christopher P Locher; Steven M Jones; Brian L Hanzelka; Emanuele Perola; Carolyn M Shoen; Michael H Cynamon; Andile H Ngwane; Ian J Wiid; Paul D van Helden; Fabrice Betoudji; Eric L Nuermberger; John A Thomson
Journal:  Antimicrob Agents Chemother       Date:  2014-12-22       Impact factor: 5.191

5.  Mycobacterium branderi from both a hand infection and a case of pulmonary disease.

Authors:  J Wolfe; C Turenne; M Alfa; G Harding; L Thibert; A Kabani
Journal:  J Clin Microbiol       Date:  2000-10       Impact factor: 5.948

6.  Antimycobacterial agents differ with respect to their bacteriostatic versus bactericidal activities in relation to time of exposure, mycobacterial growth phase, and their use in combination.

Authors:  Irma A J M Bakker-Woudenberg; Wim van Vianen; Dick van Soolingen; Henri A Verbrugh; Michiel A van Agtmael
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

7.  Programmatic implementation of rapid DST for Mycobacterium tuberculosis in Peru.

Authors:  L Asencios; G Yale; M Yagui; N Quispe; A Taylor; J Blaya; C Contreras; P Cegielski; J Bayona; C Bonilla; S Shin
Journal:  Int J Tuberc Lung Dis       Date:  2008-07       Impact factor: 2.373

8.  The efflux pump inhibitor timcodar improves the potency of antimycobacterial agents.

Authors:  Trudy H Grossman; Carolyn M Shoen; Steven M Jones; Peter L Jones; Michael H Cynamon; Christopher P Locher
Journal:  Antimicrob Agents Chemother       Date:  2014-12-22       Impact factor: 5.191

9.  Direct Determination of Pyrazinamide (PZA) Susceptibility by Sputum Microscopic Observation Drug Susceptibility (MODS) Culture at Neutral pH: the MODS-PZA Assay.

Authors:  Roberto Alcántara; Patricia Fuentes; Lisette Marin; Daniela E Kirwan; Robert H Gilman; Mirko Zimic; Patricia Sheen
Journal:  J Clin Microbiol       Date:  2020-04-23       Impact factor: 5.948
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.